Refine Results
  1. "Breast Medicine Service"
Formats
  1. Journal Article (1502)
  2. Meeting Abstract (883)
  3. Book Section (32)
  4. Conference Paper (16)
  5. Book Whole (5)
Groups
  1. Breast Medicine Service (2438)
  2. Solid Tumor Oncology Division (2438)
  3. Breast Cancer Disease Management Team (2342)
  4. Survivorship Research (1216)
  5. Population Sciences Research Program (637)
  6. Melanoma Disease Management Team (527)

More Groups

People
  1. Clifford Hudis (812)
  2. Larry Norton (530)
  3. Mark Robson (355)
  4. Neal Rosen (348)
  5. Andrew Seidman (231)
  6. Kenneth Offit (194)

More People

Years
  1. 2019 (1)
  2. 2018 (169)
  3. 2017 (184)
  4. 2016 (159)
  5. 2015 (199)
  6. 2014 (147)

More Years

Publications
  1. Journal of Clinical Oncology (399)
  2. Cancer Research (317)
  3. Breast Cancer Research and Treatment (125)
  4. Clinical Cancer Research (96)
  5. Cancer (63)
  6. Annals of Oncology (61)

More Publications

Publishers
  1. American Association for Cancer Research (504)
  2. American Society of Clinical Oncology (411)
  3. Elsevier Inc. (230)
  4. Springer (215)
  5. Nature Publishing Group (156)
  6. Oxford University Press (110)

More Publishers

Results (2438)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing
    Journal Article

    Ross, D. S.; Zehir, A.; Brogi, E.; Konno, F.; Krystel-Whittemore, M.; Edelweiss, M.; Berger, M. F.; Toy, W.; Chandarlapaty, S.; Razavi, P.; more...
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • Detecting HER2 alterations by next generation sequencing (NGS) in patients with advanced NSCLC from the United States and China
    Meeting Abstract

    Xu, C.; Zhang, Y.; Liu, D.; Shen, R.; Razavi, P.; Liu, S.; Sun, H.; Offin, M.; Drilon, A.; Rudin, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small-cell lung cancer
    Meeting Abstract

    Tsurutani, J.; Park, H.; Doi, T.; Modi, S.; Takahashi, S.; Nakagawa, K.; Krop, I.; Waqar, S.; Yoh, K.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Pan-cancer microsatellite instability to predict for presence of Lynch syndrome
    Meeting Abstract

    Latham Schwark, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Dubard-Gault, M.; Tran, C.; Middha, S.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
    Meeting Abstract

    Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer
    Meeting Abstract

    Soliman, H. H.; Robson, M. E.; Wagner, S.; Flake, D. D.; Schwartzberg, L. S.; Sharma, P.; Magliocco, A. M.; Kronenwett, R.; Lancaster, J. M.; Lanchbury, J. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Lyons, T.; Gucalp, A.; Arumov, A.; Patil, S.; Edelweiss, M.; Gorsky, M.; Troso-Sandoval, T. A.; Bromberg, J.; Sanford, R. A.; Iyengar, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial
    Meeting Abstract

    Jhaveri, K. L.; Makker, V.; Wang, X. V.; Chen, A. P.; Flaherty, K.; Conley, B. A.; O'Dwyer, P. J.; Williams, P. M.; Hamilton, S. R.; Harris, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay
    Meeting Abstract

    Gradishar, W. J.; Robson, M. E.; Flake, D. D.; Schwartzberg, L. S.; Sharma, P.; Soliman, H. H.; Magliocco, A. M.; Brown, K.; Wehnelt, S.; Gutin, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save